The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome

By F. Medeiros, M. Muto, Yonghee Lee, J. Elvin, M. Callahan, C. Feltmate, J. Garber, D. Cramer, C. Crum. American Journal of Surgical Pathology, 2006

937 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/4b7c9d4aea8dac82e8f087f2677f1ef400aa15e3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. J. Prat
2. Ie-Ming Shih
3. R. Kurman

In Oncology

1. J. Prat
2. Ie-Ming Shih
3. R. Kurman

In Reproductive Medicine

1. J. Prat
2. R. Kurman
3. Ie-Ming Shih
4. E. Lengyel

Citations in the corpus

• Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship (2007, methodology): “In selected cases, p53 immunostaining was performed to illustrate the histologic transitions from normal to TIC, as previously described.18 The histologic criteria for TIC were based on prior studies of early intraepithelial carcinomas of the fallopian tube in BRCA (+) women, similar descriptions of”
• Molecular Pathogenesis and Extraovarian Origin of Epithelial Ovarian Cancer. Shifting the Paradigm (2011, neutral): “As previously noted, in studies of ovarian and primary peritoneal HGSC in which the fallopian tubes were completely sectioned using the SEE-FIM protocol (63), STICs were identified in 50-60% of cases (66,67).”
• A candidate precursor to serous carcinoma that originates in the distal fallopian tube (2007, methodology): “Thus, we designed a protocol to systematically section fallopian tubes and to determine the frequency of this entity, termed the ‘p53 signature’, and its relationship to TIC [15].”
• The Origin and Pathogenesis of Epithelial Ovarian Cancer- a Proposed Unifying Theory (2010, result): “Subsequent studies, in which fallopian tubes were more carefully examined, confirmed that in situ and small, early invasive tubal carcinomas occurred in women with a genetic predisposition for the development of ovarian cancer.(4,5,8,12,27,29,41) This led to fallopian tube carcinoma being included a”
• FIGO staging of endometrial cancer: 2023 (2023, neutral): “…tubal involvement by serous carcinoma from the coincidental presence of an independent serous tubal intraepithelial carcinoma; in these cases, appropriate sampling (SEE-FIM protocol), 31 as well as ancillary diagnostic techniques, such as immunohistochemistry and molecular pathology, are required.”
• The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. (2016, methodology): “The detection of the lesion in the fallopian tube was due to the introduction of a new method of sampling the fallopian tube in which the entire fallopian tube, with particular attention to the fimbria, was sectioned, the so called sectioning and extensively examining the fimbria technique.(70) Subs”
• Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features (2012, methodology): “Clonality of the precursor cells in both the so-called p53 signature and STICs are the strongest support for the fimbriated end of the fallopian tube as a site of origin for HGSC [14].”